Macro­Gen­ics touts a PhI­II win in a head-to-head with best-sell­er Her­ceptin — shares rock­et high­er

Macro­Gen­ics $MGNX has claimed suc­cess in their Phase III tri­al of their drug mar­ge­tux­imab for metasta­t­ic breast can­cer, putting them on the path to a BLA fil­ing. But they’re not of­fer­ing a lot of de­tail.

The top-line num­ber cleared the bar for sta­tis­ti­cal sig­nif­i­cance, but not by a wide mar­gin.

Scott Koenig

In a head-to-head with Her­ceptin (trastuzum­ab), the biotech re­ports that their drug won out in pro­long­ing pro­gres­sion-free sur­vival among heav­i­ly treat­ed third- and fourth-line HER2+ pa­tients. The p-val­ue on the pri­ma­ry end­point was 0.033 with a 24% risk re­duc­tion for dis­ease pro­gres­sion. A much bet­ter score of 0.005, though, was record­ed for the ma­jor­i­ty of pa­tients in the tri­al who were car­ri­ers of the CD16A (FcγRI­I­Ia) 158F al­lele, which is linked to re­sis­tance to Her­ceptin.

This was a close­ly watched cat­a­lyst for Macro­Gen­ics. Its shares shot up 166% on the top-line re­port Wednes­day morn­ing. Jonathan Chang at Leerink not­ed:

Many in­vestors we have spo­ken with ex­pect­ed the study to be neg­a­tive and we be­lieve lit­tle val­ue for Her2+ mBC was baked in­to the MGNX stock. We mod­eled a 60% prob­a­bil­i­ty of suc­cess.

We don’t know yet how those num­bers trans­late to months of added PFS, or the over­all sur­vival rate. Re­searchers are still pon­der­ing OS. The more ex­act da­ta, which will tell an­a­lysts a lot more about the mar­ket po­ten­tial for this drug, will be un­veiled at a lat­er can­cer con­fer­ence.

Re­searchers will be tak­ing the da­ta from the SOPHIA study, which en­rolled 536 pa­tients, to reg­u­la­tors some­time in the sec­ond half of this year.

The com­pa­ny has been tout­ing their an­ti­body’s en­gi­neer­ing, say­ing the bet­ter Fc do­main can en­gage the im­mune sys­tem. The drug is de­signed to tar­get the HER2 on­co­pro­tein. And there’s a long way to go on the de­vel­op­ment ef­fort.

“We look for­ward to ad­di­tion­al op­por­tu­ni­ties to de­vel­op mar­ge­tux­imab in oth­er HER2-pos­i­tive breast and gas­tric can­cer pop­u­la­tions,” Macro­Gen­ics CEO Scott Koenig re­marked. 

A side ben­e­fi­cia­ry in to­day’s news is Zai Lab, $ZLAB the Chi­nese biotech that in-li­censed re­gion­al rights to the drug for a low up­front pay­ment. Jef­feries not­ed:

Re­call, ZLAB in-li­censed marge 12/2/18 for an up­front of $25M for rights to breast and gas­tric can­cer in Chi­na (our note here). Ex­pec­ta­tions for the SOPHIA ph.III read­out were low, and we be­lieve ZLAB took a cal­cu­lat­ed risk/ben­e­fit ap­proach w/ marge that led to best-case sce­nario, giv­en to­day’s news.

The biotech hit a stum­bling block at the end of last year. Leery about signs of liv­er tox­i­c­i­ty among pa­tients tak­ing a B7-H3 × CD3 bis­pe­cif­ic un­der de­vel­op­ment at Macro­Gen­ics, the FDA slapped a par­tial hold on the ear­ly-stage pro­gram.

Op­ti­miz­ing Cell and Gene Ther­a­py De­vel­op­ment and Pro­duc­tion: How Tech­nol­o­gy Providers Like Corn­ing Life Sci­ences are Spurring In­no­va­tion

Remarkable advances in cell and gene therapy over the last decade offer unprecedented therapeutic promise and bring new hope for many patients facing diseases once thought incurable. However, for cell and gene therapies to reach their full potential, researchers, manufacturers, life science companies, and academics will need to work together to solve the significant challenges facing the industry.

Pfiz­er, Sarep­ta and two oth­ers sug­gest Duchenne drug safe­ty is­sues tied to "class ef­fect"

Since the first experimental Duchenne gene therapy programs came about, the space has proven rife with safety issues and patient deaths in clinical trials. Pfizer and three biotechs now think they’ve found a reason why.

The four companies suggested there may be a “class effect” causing the adverse events in Duchenne gene therapies, they wrote in a new study. They specifically highlighted how side effects in five patients across three trials, who all showed muscle weakness with cardiac involvement, were “strikingly similar.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.

Pre­sent­ing a live End­points News event: Man­ag­ing a biotech in tur­bu­lent times

Biotech is one of the smartest, best educated industries on the planet. PhDs abound. We’ve had a long enough track record to see a new generation of savvy, experienced execs coming together to run startups.

And in these times, they are being tested as never before.

Biotech is going through quite a rough patch right now. For 2 years, practically anyone with a decent resume and some half-baked ideas on biotech could start a company and get it funded. The pandemic made it easy in many ways to pull off an IPO, with traditional road shows shut down in exchange for a series of quick Zoom meetings. Generalist investors flocked as the numbers raised soared into the stratosphere.

Pearl Huang, former Cygnal Therapeutics president and CEO

UP­DAT­ED: Flag­ship builds a new start­up out of pieces from 2 of its biotechs. And a Roche vet leaves to do some­thing new

Flagship has crafted a new startup out of pieces from a pair of fledglings in the VC’s nest. And a prominent Roche veteran who ran one of the biotechs won’t be making the next leg of the journey.

The new company is called Sonata Therapeutics, which is picking up the work that Inzen was doing related to the cellular microenvironment and combining with Flagship’s Cygnal Therapeutics, which came out of stealth more than 3 years ago and put Pearl Huang — the BeiGene founder and former Roche SVP — at the helm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.

Amidst R&D reshuf­fle, Ver­tex ex­pands its pres­ence in Boston, aim­ing to be­come num­ber one

Vertex Pharmaceuticals has been one of the buzzier names in the bustling Boston biotech scene, but now the company is looking to vault to number one status — at least in terms of physical footprint.

At a ribbon cutting on Tuesday for its new Jeffrey Leiden Center for Cell and Genetic Therapies at the Boston Seaport, Vertex announced it would embark on a new project: The company will build a 344,000 square foot facility in the seaport to accommodate the company’s growing R&D needs, especially in its cell and gene therapies program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.

Martin Shkreli (Dennis Van Tine/MediaPunch/IPX)

In­fa­mous biotech ex­ec Mar­tin Shkre­li gets out of prison, hits the street

Martin Shkreli, the infamous biotech CEO who made headlines for his jeering assault on a legion of critics in and out of Congress, is back on the streets after 4 years inside a federal penitentiary.

Shkreli’s attorney put out a statement Wednesday afternoon saying that the “pharma bro” had been transferred to a halfway house in New York with a few more months to go under federal custody, slated to end September 14. Attorney Benjamin Brafman acknowledged the release and vowed that he and Shkreli are keeping quiet.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,400+ biopharma pros reading Endpoints daily — and it's free.

De­spite fed­er­al ef­forts to di­ver­si­fy clin­i­cal tri­als, progress re­mains 'stag­nan­t' — re­port

While calls to diversify clinical trials have grown louder in recent years — gaining support from federal agencies such as the FDA and NIH — progress has largely stalled, according to a new report from the National Academies of Sciences, Engineering and Medicine.

Swaths of patients in racial and ethnic minority groups, as well as LGBTQIA+, pregnant and older adult populations continue to be left out of clinical trials. While some advances have been made in the last 30 years — women now account for roughly half of clinical trial participants — growth in other areas remains stagnant, according to the report, which was mandated by Congress and sponsored by the NIH.

Paul Chaplin, Bavarian Nordic president and CEO

Bavar­i­an Nordic se­cures BAR­DA con­tract for small­pox vac­cine

It seems that smallpox vaccination production is weighing on the mind of the US government. And manufacturer Bavarian Nordic is the latest company to benefit.

Just a few days after Emergent, a company that has made government contracts its lifeblood, acquired the exclusive rights to Tembexa from Chimerix, with a $225 million cash payment and an expected BARDA contract, the agency has offered a contract for smallpox vaccine production.

Frank Pallone (D-NJ), House Energy and Commerce Committee chair (Kevin Dietsch/Pool via AP Images)

House com­mit­tee unan­i­mous­ly ad­vances FDA user fee leg­is­la­tion with ac­cel­er­at­ed ap­proval tweaks

The House Energy and Commerce Committee on Wednesday offered a rare show of bipartisan support for a bill that would provide the FDA with user fees for the next five years.

The committee voted 55-0 to advance the quinquennial user fee bill to the full House floor, which if approved, will allow the FDA to use biopharma funds to hire new reviewers, and hit new marks as outlined in the user fee deals that the FDA and biopharma companies forged over the past several years.